Table 3.
Symptom durationa (days) in patients consulting in primary care with detected virus or no detected virus (n = 2393)
| Median (IQR) time to resolution of symptoms rated moderately bad or worse | Unadjusted hazard ratio (95% CI) | Adjusted hazard ratio (95% CI)b | |
|---|---|---|---|
| No virus(es) (n = 1288) | 6 (4–10) | (Ref) | (Ref) |
| ≥1 of six viruses (n = 1105) | 7 (5–11) | 0.93 (0.86–1.01) | 0.93 (0.86–1.02) |
| No virus(es) (n = 1288) | 6 (4–10) | (Ref) | (Ref) |
| 1 of six viruses (n = 1056) | 7 (5–11) | 0.94 (0.87–1.03) | 0.94 (0.86–1.03) |
| 2 of six viruses (n = 49) | 8 (5–15) | 0.74 (0.55–1.00) | 0.76 (0.56–1.03) |
| CoV (n = 177)c | 7 (4–11) | 0.92 (0.78–1.09) | 0.95 (0.80–1.12)d |
| hMPV (n = 108)c | 8 (6–12) | 0.80 (0.65–0.98) | 0.77 (0.62–0.94)d |
| Influenza (n = 243)c | 7 (5–10) | 1.12 (0.97–1.28) | 1.08 (0.93–1.24)d |
| PiV (n = 60)c | 8 (5–11) | 0.98 (0.75–1.28) | 0.97 (0.74–1.26)d |
| Rhinovirus (n = 445)c | 7 (5–11) | 0.90 (0.81–1.01) | 0.93 (0.83–1.04)d |
| RSV (n = 121)c | 8 (5–14) | 0.79 (0.65–0.96) | 0.80 (0.65–0.96)d |
A hazard ratio <1 indicates a disadvantageous effect on symptom resolution. CI, confidence interval; CoV, coronavirus; hMPV, human metapneumovirus; IQR, interquartile range; Piv, parainfluenza; RSV, respiratory syncytial virus.
Calculated as the median (IQR) number of days with symptoms rated moderately bad or worse by the patient following initial presentation.
Estimates controlled for age, gender, pulmonary comorbidities (asthma, chronic obstructive pulmonary disease and other lung diseases), heart failure, current smoking, influenza vaccination during the preceding fall or winter, coinfection with at least one respiratory bacterium or with Aspergillus and duration of symptoms before presentation.
Reference group is no CoV, hMPV, influenza virus, PiV, rhinovirus or RSV, respectively.
By including all six viruses in the model, estimates were additionally controlled for coinfection with another respiratory virus.